Navigation Links
Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
Date:10/18/2011

t timelines, future IND filings for new product candidates, and regulatory filings and submissions for any of our product candidates in clinical development; fluctuations in our operating results, in particular if EYLEATM or any of our other late-stage product candidates is approved for marketing, and our revenues, market share, and/or market acceptance of EYLEATM or such other products do not meet the expectations of investors or analysts; the possible success of any of our current or future product candidates; the determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our product and drug candidates; pricing or reimbursement actions or decisions by government authorities or insurers affecting the coverage or reimbursement of any of our product candidates or competitive products; our ability to raise additional capital as needed on favorable terms; public concern as to the safety or effectiveness of any of our product candidates; the uncertainty of market acceptance of our product and drug candidates; our ability to advance new antibody product candidates into clinical development; our ability to build a successful, integrated biopharmaceutical company; competing drugs that may be superior to our product and drug candidates; the data that will be generated by ongoing and planned clinical trials and the ability to use that data to support regulatory filings, including potential applications for marketing approval for any of our product candidates; the maintenance of any of our license or collaborative relationships, including, without limitation, those with Sanofi and Bayer HealthCare; our liquidity and our expectations regarding our future cash needs and our expectations regarding the possibility of raising additional capital; the risks associated with third party intellectual property and pending or future litigation relating thereto; and completion of this offering a
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 MGC Diagnostics Corporation ... a conference call to discuss its financial results for ... 2014. The call will be at 4:30 p.m. ET ... financial results for the third quarter of fiscal 2014 ... Participants can dial (877) 317-6789 or ...
(Date:8/28/2014)... SAN ANTONIO , Aug. 28, 2014 ... therapeutics for the treatment of cancer, announces the recent ... the journal Steroids . The recent ... below), reviews the evolution and development of GenSpera,s prodrug technology ... activity of thapsigargin (from the plant Thapsia garganica ...
(Date:8/28/2014)... 2014 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... data from trials evaluating the use of collagenase clostridium histolyticum ... adult patients with a palpable cord will be presented at ... Society for Surgery of the Hand (ASSH) being held in ... ® (CCH) is a biologic approved in the U.S., ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Third Quarter Fiscal 2014 Financial Results on Tuesday, September 9, 2014 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
... Cognizant (NASDAQ: CTSH ), a ... outsourcing services, today announced a multi-year agreement with ... services to generate clinical study reports. ... statistical programming, statistical analysis, medical writing, and document ...
... 29, 2011  Buffalo Heart Group, LLP, 2011 :  Today ... of the AngelMed Guardian cardiac monitor and alert system. The ... to get to the emergency room during an impending heart ... state of New York, and is among the very first ...
Cached Medicine Technology:Cognizant to Deliver Comprehensive Biostatistics and Medical Reporting Services for AstraZeneca 2Cognizant to Deliver Comprehensive Biostatistics and Medical Reporting Services for AstraZeneca 3Buffalo Heart Group Investigates Early Heart Attack Detection Device Developed By Angel Medical Systems 2
(Date:8/28/2014)... Twenty seven per cent of rheumatoid arthritis patients in ... known as anti-TNF therapies did not take them as ... Royal Infirmary were among those from 60 hospitals around ... the Arthritis Research UK Centre for Genetics and Genomics ... warned that failure to take the drugs correctly, known ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 AmeriPride Services, ... America, today announced the launch of its new Customer ... AmeriPride even easier and more convenient for customers. The ... online and better communicate with the company. , Features ... Access, download and pay bills ...
(Date:8/28/2014)... Clarity PSO , an operating division of ... Patient Safety Organization (PSO) for another three-year period under ... Quality (AHRQ). Clarity PSO will continue to provide valuable ... true intentions of the Patient Safety and Quality Improvement ... eager to continue our journey as a PSO and ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Genetic ... available throughout the world, with large reference laboratories ... Since laboratories differ with regard to the genetic ... costs, payers may struggle to find the most ... To help clients sort through these differences, Hayes, ...
(Date:8/28/2014)... veEDIS Clinical Systems, LLC has successfully ... in Lawrence Medical Center, located in Moulton, Alabama. ... patient care, veEDIS is a key ingredient in ... the authorized, confidential exchange of patient information at ... designed in accordance with clinical workflows and best ...
Breaking Medicine News(10 mins):Health News:Arthritis patients failing to take expensive medication, according to new research 2Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3
... U.S. HIV/AIDS Atlas , , WASHINGTON, June 22 ... Atlas ( http://www.MapHIV.org ) that highlights ... United States. The Atlas makes information on HIV/AIDS prevalence ... painting a comprehensive picture of the varying intensity of the ...
... Hoag ... of Cardiology) as its executive medical director of the Hoag Heart and Vascular Institute (HHVI). ... Newport Beach, Calif. ... Tancredi, M.D., F.A.C.C. (Fellow of the American College of Cardiology) as its executive medical director ...
... Time for Fitness! , , LOS ANGELES, June 22 ... the park or along the beach. Now a brand new product ... equipment on wheels, but with a unique design to allow your ... new concept of fitness, will be introduced to California starting from ...
... study finds, , MONDAY, June 22 (HealthDay News) -- ... blood pressure, but new research finds those extra pounds can ... especially if she experiences early menopause. , Published in the ... found that women with a body-mass index (BMI) greater than ...
... CRO expertise in $1 billion market for cancer support ... , WATERTOWN, Mass., June 22 Biomodels LLC, ... today announced that its customized research program allowed ActoGeniX ... Food and Drug Administration (FDA) approval for Phase 1b ...
... LLC, the rising star of the Sports Nutrition Industry, ... each of Vitamin Shoppe,s 400+ locations nationwide. , ... of our entire line of products," MUSCLEPHARM president Brad ... in nearly every neighborhood across the nation! Vitamin Shoppe ...
Cached Medicine News:Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 2Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 3Health News:Nationally Acclaimed Cardiologist Joins Hoag Heart and Vascular Institute as Executive Medical Director 2Health News:Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 2Health News:Obesity Greatly Raises Endometrial Cancer Risk 2Health News:Obesity Greatly Raises Endometrial Cancer Risk 3Health News:Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients 2Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2
... The design of the Hi-Top ... to be held back in ... shoe counter. The front is ... and compression on the toes. ...
... semi-rigid post op shoe is ideal for ... breathable upper will keep your patient both ... closure provides even tension and compression. The ... support for your patient. The black TPR ...
Comfortably positions the affected foot at 90 to provide continuous and effective stretching of the plantar fascia and Achilles Tendon...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: